The Global SERD (selective estrogen receptor degrader) Therapeutics Market size was accounted at USD 1.3 Bn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 17.9% from 2022 to 2030. Selective estrogen receptor degrader (SERD) is a type of drug which downregulates the estrogen receptor. SERD treats estrogen receptor-positive breast cancer. SERD therapy can be used as both monotherapies and in combination with other therapeutic agents. Many key market players are engaged in developing new breast cancer therapies that would propel the growth of this market.
Major driving factors in the SERD therapeutics market are the increasing need for SERD therapies, the high prevalence of breast cancer, the rising number of clinical trials, and increasing investments by key players in the development of promising treatments. Furthermore, advanced medical technologies, growth in the population, and a growing number of health-conscious people will enhance the growth of the SERD therapeutics market during the forecast period. However, the high price of devices, complex procedures, lack of strict government laws, and resistance to endocrine Therapy are limiting the growth of this market.
The SERD therapeutics market is segmented into Products, Therapy and Region. The Products segment is further bifurcated into Faslodex, RAD1901, GDC-9545, AZD9833, SAR439859, and Other Generics. SAR439859 is expected to dominate this market over the forecast period due to its safety and efficacy. By Therapy, the market is segmented into First-Line Treatment and Second-Line Treatment. Regionally, the SERD therapeutics market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, followed by Europe, holds the maximum share of this market due to increased research and development expenditure, major market players, and the fast adaption of advanced technologies.
Major vital Players in the SERD therapeutics market are Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr Reddy’s Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC., Zentalis Pharmaceuticals, and List of Other Prominent Players.
Companies Mentioned
- Amneal Pharmaceuticals Inc
- AstraZeneca, Plc.
- Reddy’s Laboratories
- Eli Lilly and Company
- G1 Therapeutics, Inc.
- Glenmark Pharmaceuticals
- HBT Labs, Inc
- Hoffmann-La Roche AG
- InventisBio
- Novartis AG
- Radius Health
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Zenopharm LLC.
- Zentalis Pharmaceuticals
- List of Other Prominent Players
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Therapy
